🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

M Sakamoto

University of Colorado Cancer Center

ORCID: 0000-0002-1570-5076

Also affiliated with University of Colorado Denver

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance”.

Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance

npj Precision Oncology(2023)10.1038/s41698-023-00381-0

N/A

0DataRank · unranked

8 citations

Tejas Patil, M Sakamoto

The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations

Lung Cancer(2024)10.1016/j.lungcan.2024.108040

N/A

0DataRank · unranked

10 citations

Dexiang Gao, Alexander Watson, M Sakamoto, Yunan Nie, A.J. Gibson +13 more

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100637

N/A

0DataRank · unranked

8 citations

Alyse Staley, Yunan Nie, M Sakamoto, Margaret Stalker, James Jurica +17 more